Viewing Study NCT00479934


Ignite Creation Date: 2025-12-25 @ 2:36 AM
Ignite Modification Date: 2026-01-06 @ 6:53 AM
Study NCT ID: NCT00479934
Status: COMPLETED
Last Update Posted: 2011-03-04
First Post: 2007-05-29
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Efficacy and Safety of Imatinib in Scleroderma
Sponsor: University Hospital, Bordeaux
Organization:

Study Overview

Official Title: Phase II Randomized Double Blind Clinical Trial of'Imatinib Mesylate STI571 (GlivecĀ®) Versus Placebo in Patients With Severe Cutaneous Scleroderma or Systemic Sclerosis With Severe Cutaneous Involvement.
Status: COMPLETED
Status Verified Date: 2011-03
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: SCLEROGLIVEC
Brief Summary: In vitro studies have shown that imatinib 1mM inhibits strongly the growth of cutaneous fibroblasts. The hypothesis is that imatinib inhibits PDGFR which is known to be a potential target for the molecule, as recently also proposed after the discovery of autoantibodies activating the PDGF receptors. Recent data indicate that TGFb is also a potential target of imatinib. Cutaneous scleroderma is characterized by progressive cutaneous fibrosis caused by hyperactive dermal fibroblasts. Since no established treatment for skin sclerosis in scleroderma is currently available. This study will test the safety and efficacy of imatinib in the treatment of patients with scleroderma and severe cutaneous involvement.
Detailed Description: This study will test the efficacy and tolerance of patients with a high score of induration (modified Rodnan score \> 20/54) Comparison : 34 patients with severe forms of cutaneous involvement will be evaluated in a double blind RCT comparing imatinib 400mg/j and placebo in a 6 month period. Efficacy will be assessed using a cutaneous induration scale and skin biopsy, and quality of life questionnaires.

Study Oversight

Has Oversight DMC: True
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?:

Secondary ID Infos

Secondary ID Type Domain Link View
2006/017 None None View